News | January 27, 2022
Moderna working on Omicron-specific booster candidate
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
The six-layer packaging ensures that external media such as bacteria, light and air do not contaminate the liquid
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
The country is sixth among the most affected countries by active cases
Previously, the use of the drug was limited to patients requiring hospitalization
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
An article by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center, has been published in medRxiv
Krivida Novus can detect the Omicron variant and its sub-lineages in 45 minutes
Yoga helps to build a strong immune system and daily breathing regime of 10-minute helps in the long run
Subscribe To Our Newsletter & Stay Updated
